

BP-50649

Vanucizumab - anti-human VEGF-A/Ang-2 Bispecific Antibody

Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects.

Product Details	
Species Reactivity	Human
Source	Mammalian Cells
Isotype	Human IgG1 kappa
Class	Anti-Human Bispecific antibodies
Type	Recombinant Humanized
Clone	SP34-2/OKT3
Target	Anti-human VEGF-A and angiopoietin-2 (Ang-2)
Purity	>95%
Molecular Weight	14146.89 kDa
CAS Number	1448221-05-3
Formulation	NA
Storage conditions	Store at -80°C for 2 years. Aliquots should be stored at the same temperature after first use to avoid multiple freeze-thaws.